Cumulative incidence of relapse by randomization groups.
Cumulative incidence of relapse was 29% at 1 year.
The cumulative incidence of relapse was 30% at 7 years.
There was, however, a reduction in the cumulative incidence of relapse in the ASCT arm, which reached the statistical significance level.
In these patients, estimated 10-year DFS and cumulative incidence of relapse were 35%9595% CI, 26 44%) and 58%9595% CI, 48 67%), respectively.
Even if the cumulative incidence of relapse was reduced in the ASCT arm, DFS and overall survival were not significantly improved.
At 10 years, the cumulative incidence of relapse was 84% in the CHEMO arm versus 76% in the ASCT arm (P=0.08).
Conclusions: The incidence of relapse among children is lower than that observed among adults and varies with age.
Overall survival (OS), cumulative incidence of relapse (CIR), and nonrelapse mortality (NRM) after allo-HSCT were analyzed.
The trend for a lower incidence of relapse associated with ASCT in high-risk patients from the LALA-94 trial, while not in corresponding patients from LALA-84/8 LALA-84/8underlines the value of this approach.
In the remaining 300 rapid responders, estimated 10-year cumulative incidence of relapse was 61% in the ASCT arm as compared to 76% in the CHEMO arm (P=0.01).
